Advances in Gut Microbiome and Metabolomics Research in the Comorbidity of Inflammatory Bowel Disease and Depressive Disorder
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Chengyuan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandon…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Inflammatory Bowel Diseases, Metabolomics, Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Science and Technology Plan Project of Jinan.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic autoimmune disorder characterized by persistent inflammation of the gastrointestinal tract, with a substantial proportion of patients experiencing comorbid depressive disorders. This comorbidity profoundly affects patients' long‐term prognosis and quality of life. Emerging evidence suggests that the interplay between IBD and depression may be mediated by disruptions in the gut microbiome and metabolome. Notably, alterations in gut microbial composition and metabolic profiles observed in both IBD and depression indicate potential shared pathophysiological mechanisms, which could inform novel therapeutic strategies. This review aims to summarize recent advances in gut microbiome and metabolomics research related to IBD comorbid with depression, highlighting their implications for disease management and treatment. First, we provide an overview of the epidemiological features of IBD comorbid with depressive disorder, as well as the underlying pathophysiological mechanisms that may contribute to their bidirectional relationship. Subsequently, we highlight key microbiome and metabolite alterations observed in comorbid patients, which may contribute to disease onset and progression. At last, we also discuss emerging microbiota‐ and metabolite‐based therapeutic approaches that hold promise for improving both gastrointestinal and psychological outcomes. In conclusion, integrating microbiome and metabolomics perspectives provides novel insights into the shared pathophysiology of IBD and depressive disorders and may inform the development of more effective and personalized interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering Research Center of Minimally Invasive Diagnosis and Trea…
- Center for Big Data Research in Health and Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Data Open Innovative Application Laboratory, Ji…
- School of Public Health, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
ORCID-Profile: Fang Tang
Förderung
- Science and Technology Plan Project of Jinan
Zitieren
APA
Zhao, C., Lao, J., Cao, J., Yang, Y., Liu, C., & Tang, F. (2026). Advances in Gut Microbiome and Metabolomics Research in the Comorbidity of Inflammatory Bowel Disease and Depressive Disorder. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70173
Vancouver
Zhao C, Lao J, Cao J, Yang Y, Liu C, Tang F. Advances in Gut Microbiome and Metabolomics Research in the Comorbidity of Inflammatory Bowel Disease and Depressive Disorder. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70173
BibTeX
@article{Zhao2026,
author = {Zhao, Chengyuan and Lao, Jiahui and Cao, Jia and Yang, Yang and Liu, Changhong and Tang, Fang},
title = {Advances in Gut Microbiome and Metabolomics Research in the Comorbidity of Inflammatory Bowel Disease and Depressive Disorder},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70173}
}
EUVIMED